HAEMATO PHARM GmbH specializes in the manufacture and sale of generics and EU original medicines. With its product portfolio, the company focuses on five major therapeutic areas: HIV / AIDS, Neurology, Oncology, Rheumatology and Urology.
HAEMATO MED GmbH is an innovative healthcare company specializing in the development and commercialization of pharmaceutical, medical and medical devices for aesthetic surgery and cosmetic dermatology.
HAEMATO AG is a publicly traded pharmaceutical company focusing on the growth markets of high-end specialty pharmaceuticals in the indication areas of oncology and HIV as well as in the areas of rheumatism, neurology and cardiovascular diseases. In addition, the in-house development of innovative medical devices for the beauty market was started. HAEMATO AG assumes that first products will hit the market in the coming year, which has already created the basis for further growth and additional income.
We inform you about the current business development of HAEMATO AG and about our investor relations activities.
In the third quarter of 2018 HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS consolidated sales of EUR 69.12 million (previous year: EUR 72.5 million). In the considered period of January till September 2018 the sales amounted to € 212.8 million...read more
In the first half of 2018, the HAEMATO Group increased sales by 3.6 % year-on-year to a total of EUR 143.7 million. EBIT amounted to kEUR 6,484.6 (prior year period: kEUR 3,182.8). The consolidated profit as of 30.06.2018 amounts to kEUR 5,044.5 and is...read more
HAEMATO AG announced today that the shareholders of the company have approved with a large majority all items on the agenda which were put to the vote by the administration at the Annual General Meeting on July 4, 2018 in Berlin. At the vote on agenda...read more
Get an overview of the current status and development of HAEMATO AG. Here you will find information on the current status of the Group and on developments in recent years.
Do you have any questions or suggestions? We look forward to hearing from you.